Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen with Doxorubicin and Docetaxel in Breast Cancer
NCT00063934Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Feb 2008
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oblimersen in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Number of Participant With Toxicities and Pathologic Complete Response. Started May 2003; status: terminated.
02
Drugs
oblimersen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00063934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063934.